Johnson & Johnson (JNJ) Intangibles (2009 - 2026)
Johnson & Johnson (JNJ) posted Intangibles of $49.1 billion for Q1 2026, down 2.66% sequentially from $50.4 billion in Q4 2025, and up 33.48% YoY from $36.8 billion in Q1 2025.
Johnson & Johnson (JNJ) Intangibles (2009 - 2026) Analysis & Trends
Johnson & Johnson (JNJ) has 18 years of Intangibles data on file, last reported at $49.1 billion in Q1 2026.
- Quarterly Intangibles rose 33.48% year-over-year to $49.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $49.1 billion (up 33.48% YoY) and the FY2025 annual result came in at $50.4 billion, up 33.99% from the prior year.
- Intangibles eased to $49.1 billion in Q1 2026 per JNJ's latest filing, from $50.4 billion in the prior quarter.
- The five-year high for Intangibles was $50.4 billion in Q4 2025, with the low at $34.2 billion in Q4 2023.
- Average Intangibles over 5 years is $42.3 billion, with a median of $41.4 billion recorded in 2022.
- Year-over-year, Intangibles fell 27.74% in 2024 and jumped 33.99% in 2025.
- Johnson & Johnson's Intangibles stood at $40.3 billion in 2022, then retreated by 15.27% to $34.2 billion in 2023, then climbed by 10.07% to $37.6 billion in 2024, then jumped by 33.99% to $50.4 billion in 2025, then dropped by 2.66% to $49.1 billion in 2026.
- Business Quant data shows JNJ's Intangibles at $49.1 billion in Q1 2026, $50.4 billion in Q4 2025, and $48.7 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 7.37 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 49.06 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 50.87 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 36.91 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 25.75 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 21.38 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 16.38 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 52.56 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | 11.30 Bn |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | 9.05 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 49.06 Bn |
| Dec 28, 2025 | 50.40 Bn |
| Sep 28, 2025 | 48.74 Bn |
| Jun 29, 2025 | 49.84 Bn |
| Mar 30, 2025 | 36.76 Bn |
| Dec 29, 2024 | 37.62 Bn |
| Sep 29, 2024 | 39.49 Bn |
| Jun 30, 2024 | 39.73 Bn |
| Mar 31, 2024 | 34.29 Bn |
| Dec 31, 2023 | 34.18 Bn |
| Oct 1, 2023 | 35.02 Bn |
| Jul 2, 2023 | 46.25 Bn |
| Apr 2, 2023 | 47.45 Bn |
| Jan 1, 2023 | 38.49 Bn |
| Oct 2, 2022 | 40.34 Bn |
| Jul 3, 2022 | 42.41 Bn |
| Apr 3, 2022 | 44.42 Bn |
| Jan 2, 2022 | 46.39 Bn |
| Oct 3, 2021 | 47.78 Bn |
| Jul 4, 2021 | 50.24 Bn |